TrialAnnals of surgical oncology2024

Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A021501).

Rebecca A Snyder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.